News
For the most recent news and press releases, visit our investor relations website: www.ir.icecure-medical.com
IceCure Receives FDA Clearance for Expanded Indications of Cryoablation Technology and Regulatory Approval of New MultiSense System; Plans to Increase U.S. Presence and Operations
Expands Use of Cryoablation Technology to Treat Liver and Kidney Tumors. Read more here
ICECURE GIVES NOTICE OF ANNUAL SHAREHOLDERS MEETING OF THE COMPANY, DEC 26, 12:00
Notice is hereby given of the convening of a special general meeting for the shareholders of IceCure, to be held on Thursday, December 26, 2019,
IceCure Medical Appoints Medical Device Veteran Sharon Levita to its Board of Directors
Ms. Levita is a medical device veteran and brings extensive financial and business management experience in developing successful companies. Read more here
IceCure Medical Delivers Conference Call Investor Update Sept 2019
IceCure CEO, Eyal Shamir and CFO, Ronen Tsimerman update on IceCure progress in investor conference call, Sept 2019. Listen to the full conference call here.
IceCure Medical Forges Landmark Strategic Deal with Global Medical Company, Terumo Corporation
The exclusive distribution agreement, supported by Terumo’s strong commitment, will accelerate commercialization of its ProSense™ cryoablation system to treat breast cancer tumors in Japan and
IceCure Receives Israeli AMAR Approval for Use of its Freezing Technology in Specific Indications, Following an Earlier General Approval
The AMAR approval allows for freezing of benign and malignant tumors including breast, lungs, bones, liver, lymphatic tissue, lymph nodes and endocrine glands. This achievement
IceCure Receives FDA Clearance for Expanded Indications of Cryoablation Technology and Regulatory Approval of New MultiSense System; Plans to Increase U.S. Presence and Operations
Expands Use of Cryoablation Technology to Treat Liver and Kidney Tumors. Read more here
ICECURE GIVES NOTICE OF ANNUAL SHAREHOLDERS MEETING OF THE COMPANY, DEC 26, 12:00
Notice is hereby given of the convening of a special general meeting for the shareholders of IceCure, to be held on Thursday, December 26, 2019,
IceCure Medical Appoints Medical Device Veteran Sharon Levita to its Board of Directors
Ms. Levita is a medical device veteran and brings extensive financial and business management experience in developing successful companies. Read more here
IceCure Medical Delivers Conference Call Investor Update Sept 2019
IceCure CEO, Eyal Shamir and CFO, Ronen Tsimerman update on IceCure progress in investor conference call, Sept 2019. Listen to the full conference call here.
IceCure Medical Forges Landmark Strategic Deal with Global Medical Company, Terumo Corporation
The exclusive distribution agreement, supported by Terumo’s strong commitment, will accelerate commercialization of its ProSense™ cryoablation system to treat breast cancer tumors in Japan and
IceCure Receives Israeli AMAR Approval for Use of its Freezing Technology in Specific Indications, Following an Earlier General Approval
The AMAR approval allows for freezing of benign and malignant tumors including breast, lungs, bones, liver, lymphatic tissue, lymph nodes and endocrine glands. This achievement